12.01.2025 19:04:51
|
Exagen Gets Conditional Approval For New Lupus And RA Biomarker Assays In New York
(RTTNews) - Exagen Inc. (XGN), a provider of autoimmune testing, said that it has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) biomarker assays, with a planned commercial launch in January 2025.
The company noted that its new systemic lupus erythematosus and rheumatoid arthritis biomarkers will be incorporated into the AVISE CTD platform. Collectively, the company expects the new biomarkers will further improve the clinical utility of AVISE CTD, and provide clinicians with the information they need to definitively diagnose patients and shorten their autoimmune diagnostic journeys.
For the fourth quarter, the company projects net loss to be in the range of $3.4 million to $4.4 million and revenue of $13.3 million to $13.8 million.
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Exagen Inc Registered Shsmehr Nachrichten
11.11.24 |
Ausblick: Exagen zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) |
Analysen zu Exagen Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
Exagen Inc Registered Shs | 4,46 | -0,89% |
|